Napo Pharmaceuticals, Inc. Enters Finder’s Agreement With Luye Pharma Group Ltd. for Development of Crofelemer in China

SAN FRANCISCO--(BUSINESS WIRE)--Napo Pharmaceuticals, Inc., which focuses on the development and commercialization of proprietary pharmaceuticals for the treatment of diarrheal diseases in the global marketplace in collaboration with local partners, is pleased to announce the formation of a Finder’s Agreement with its licensee for crofelemer in China, Luye Pharma Group Ltd. (formerly Asiapharm).

MORE ON THIS TOPIC